➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Moodys
Merck
McKinsey
Medtronic

Last Updated: July 11, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,056,057


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,056,057 protect, and when does it expire?

Patent 9,056,057 protects INVELTYS and is included in one NDA.

This patent has eleven patent family members in seven countries.

Summary for Patent: 9,056,057
Title:Nanocrystals, compositions, and methods that aid particle transport in mucus
Abstract: Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.
Inventor(s): Popov; Alexey (Waltham, MA), Enlow; Elizabeth M. (Waltham, MA), Bourassa; James (Somerville, MA), Gardner; Colin R. (Concord, MA), Chen; Hongming (Belmont, MA), Ensign; Laura M. (Towson, MD), Lai; Samuel K. (Carrboro, NC), Yu; Tao (Baltimore, MD), Hanes; Justin (Baltimore, MD), Yang; Ming (Towson, MD)
Assignee: Kala Pharmaceuticals, Inc. (Waltham, MA) The John Hopkins University (Baltimore, MD)
Application Number:13/886,493
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Delivery; Dosage form;

Drugs Protected by US Patent 9,056,057

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Kala Pharms Inc INVELTYS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210565-001 Aug 22, 2018 RX Yes Yes   Start Trial   Start Trial Y A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Colorcon
Harvard Business School
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.